Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia
Autore:
Schaich, M; Illmer, T; Seitz, G; Mohr, B; Schakel, U; Beck, JF; Ehninger, G;
Indirizzi:
Univ Hosp Carl Gustav Carus, Dept Med 1, D-01307 Dresden, Germany Univ Hosp Carl Gustav Carus Dresden Germany D-01307 307 Dresden, Germany Univ Tubingen, Childrens Hosp, Dept Pediat Hematol & Oncol, D-72074 Tubingen, Germany Univ Tubingen Tubingen Germany D-72074 Oncol, D-72074 Tubingen, Germany Univ Greifswald, Childrens Hosp, Dept Pediat Hematol & Oncol, D-17487 Greifswald, Germany Univ Greifswald Greifswald Germany D-17487 , D-17487 Greifswald, Germany
Titolo Testata:
HAEMATOLOGICA
fascicolo: 5, volume: 86, anno: 2001,
pagine: 470 - 477
SICI:
0390-6078(200105)86:5<470:TPVOBG>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOGENOUS LEUKEMIA; CLINICAL-SIGNIFICANCE; BAX EXPRESSION; MESSENGER-RNA; PROTEIN; CELLS; CHEMOTHERAPY; TRANSCRIPTS; FREQUENCY; APOPTOSIS;
Keywords:
Bcl-2; Bcl-XL; Bax; AML; mdr1; treatment response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Schaich, M Univ Hosp Carl Gustav Carus, Dept Med 1, Fetscherstr 74, D-01307 Dresden, Germany Univ Hosp Carl Gustav Carus Fetscherstr 74 Dresden Germany D-01307
Citazione:
M. Schaich et al., "The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia", HAEMATOLOG, 86(5), 2001, pp. 470-477

Abstract

Background and Objectives. There is growing evidence that altered expression of genes belonging to the BcL-2 family of apoptosis regulators might influence chemotherapy-induced apoptosis in malignant cells and therefore could confer multidrug resistance. So far expression studies of apoptosis-regulating genes on acute myeloid leukemia (AML) have mainly focused on Bcl-2 itself and most of them have not included other factors involved in drug resistance or apoptosis as parameters determining response to chemotherapy, disease progression and survival. Design and Methods. We therefore examined Bcl-2, Bcl-XL and Bar gene expression in 235 adult patients with de novo or secondary myeloid leukemia. Theexpression levels were correlated with established prognostic factors suchas age, cytogenetic aberrations, mdr1 gene expression and clinical outcomeIn a multivariate analysis. Results. Bcl-2 and Bcl-XL positive patient had a much lower white blood cell counts than negative patient (p <0.001 and p=0.003, respectively). Bcl-2expression correlated with FAB subtype MO (p=0.03), Bar with M5b (p=0.02) and Bcl-XL with M6 (p=0.005). Mdr1 expression was more frequently seen in Bcl-2 and Bcl-XL positive patients (p-0.03 and p=0.02, respectively). Remarkably Bar was significantly less frequently expressed in de novo AML patients with high risk cytogenetics (p=0.007). No difference in expression was recognized for Bcl-2 or Bcl-XL when statistical analyses were done for cytogenetic risk groups. However, in the multivariate analysis regarding the group of de novo AML patients I 60 years with intermediate risk cytogenetics, Bcl-XL expression was found to be an independent negative prognostic factor for response to induction therapy (p=0.04). In contrast, no prognostic impact of Bcl-XL expression on treatment response was seen within the group of patients with high risk cytogenetic findings. Neither Bcl-2 nor Bar nor Bcl-XL expression had a significant influence on overall or disease-free survival. Interpretation and Conclusions. These data indicate that the prognostic value of Bcl-XL gene expression for treatment response in AML patients less than or equal to 60 years is dependent on cytogenetics. (C) 2001, Ferrata Storti Foundation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 14:35:56